EyePoint, Inc. EYPT Product Rights Agreement — Upfront Cash Payment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by EyePoint, Inc. in its filing.
Tagged under the XBRL concept eypt:UpfrontCashPayment.
The source filing: EyePoint, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211870
Additionally, pursuant to the PRA, the Company transferred and assigned to ANI certain assets and certain contracts with third parties related to YUTIQ®, including the new drug application for YUTIQ® (collectively, the Asset Transfer). Pursuant to the PRA, ANI paid the Company a $75.0 million upfront payment (the Upfront Payment). ANI also made four quarterly payments of $1.875 million to the Company totaling $7.5 million during 2024. ANI will also pay royalties to the Company from 2025 to 2028 at a percentage of low-to-mid double digits of ANI’s related U.S. annual net sales of certain products (including YUTIQ®) in excess of certain thresholds, beginning at $70 million in 2025, and increasing annually thereafter. Upon ANI’s payment of the Upfront Payment and the 2024 quarterly payments, the licenses and rights granted to ANI automatically became perpetual and irrevocable. Payments received from ANI are non-refundable.
Item 1. Unaudited Financial Statements
FAQ
- What is EyePoint, Inc.'s product rights agreement — upfront cash payment?
- EyePoint, Inc. (EYPT) reported product rights agreement — upfront cash payment of $75M in Q1 2026.
- How has EyePoint, Inc.'s product rights agreement — upfront cash payment changed year-over-year?
- EyePoint, Inc.'s product rights agreement — upfront cash payment decreased by 0.0% year-over-year, from $75M to $75M.
- What does product rights agreement — upfront cash payment mean?
- Represents the initial, non-refundable cash consideration received or paid at the inception of a licensing or product rights agreement. This metric reflects the immediate capital exchange for granting or acquiring access to intellectual property or commercialization rights. It serves as a key indicator of the initial valuation and commitment level between contracting parties.
Ask your AI about EyePoint, Inc.'s product rights agreement — upfront cash payment.
Connect your AI assistant and compare it to peers, right in your chat.
